---
document_datetime: 2023-09-21 18:33:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/budesonideformoterol-teva-pharma-bv-epar-all-authorised-presentations_en.pdf
document_name: budesonideformoterol-teva-pharma-bv-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7621726
conversion_datetime: 2025-12-22 10:03:40.372663
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number   | (Invented) name                        | Strength        | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size             |
|------------------|----------------------------------------|-----------------|-----------------------|---------------------------|-----------------------|-----------------------|
| EU/1/14/950/001  | Budesonide/Formoterol Teva Pharma B.V. | 160 µg / 4.5 µg | Inhalation powder     | Inhalation use            | inhaler               | 1 inhaler (120 doses) |
| EU/1/14/950/002  | Budesonide/Formoterol Teva Pharma B.V. | 320 µg / 9 µg   | Inhalation powder     | Inhalation use            | inhaler               | 1 inhaler (60 doses)  |

<!-- image -->